Disease Risk-Associated Genetic Variants in and Function in a Complementary Manner to Increase Pattern-Recognition Receptor-Induced Outcomes in Human Macrophages

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2020 Jul 15

PMID 32661180

Citations 4

Authors

Matija Hedl

Rui Sun

Clara Abraham

Affiliations

Soon will be listed here.

Abstract

STAT proteins can regulate both pro- and anti-inflammatory cytokine signaling. Therefore, identifying consequences of modulating expression of a given STAT is ultimately critical for determining its potential as a therapeutic target and for defining the mechanisms through which immune-mediated disease variants in genes contribute to disease pathogenesis. Genetic variants in the region are associated with multiple immune-mediated diseases, including inflammatory bowel disease (IBD). These diseases are characterized by dysregulated cytokine secretion in response to pattern-recognition receptor (PRR) stimulation. We found that the common IBD-associated rs1517352 C risk allele increased both STAT1 and STAT4 expression in human monocyte-derived macrophages (MDMs). We therefore hypothesized that the variant might regulate PRR-initiated responses in a complementary and cooperative manner because of the important role of autocrine/paracrine cytokines in modulating PRR-initiated signaling. STAT1 and STAT4 were required for PRR- and live bacterial-induced secretion of multiple cytokines. These outcomes were particularly dependent on PRR-initiated autocrine/paracrine IL-12-induced STAT4 activation to generate IFN-γ, with autocrine IFN-γ then signaling through STAT1. STAT1 and STAT4 also promoted bacterial-induced cytokines in intestinal myeloid cells and PRR-enhanced antimicrobial pathways in MDMs. Importantly, MDMs from rs1517352 C IBD risk allele carriers demonstrated increased TLR4-, IFN-γ- and IL-12-induced STAT1 and STAT4 phosphorylation and cytokine secretion and increased TLR4-enhanced antimicrobial pathways. Taken together, STAT1 and STAT4 expression is coregulated by a shared genetic region, and -immune disease-associated variants modulate IFN-γ- and IL-12-associated outcomes, and in turn, PRR-induced outcomes, highlighting that these genes cooperate to regulate pathways relevant to disease pathogenesis.

Citing Articles

STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer.

El Ahanidi H, El Azzouzi M, Addoum B, Tetou M, Hassan I, Al Bouzidi A Mol Clin Oncol. 2025; 22(4):33.

PMID: 39989605 PMC: 11843079. DOI: 10.3892/mco.2025.2828.

Origin and Function of Monocytes in Inflammatory Bowel Disease.

Liao X, Liu J, Guo X, Meng R, Zhang W, Zhou J J Inflamm Res. 2024; 17:2897-2914.

PMID: 38764499 PMC: 11100499. DOI: 10.2147/JIR.S450801.

Single-cell map of dynamic cellular microenvironment of radiation-induced intestinal injury.

Lu H, Yan H, Li X, Xing Y, Ye Y, Jiang S Commun Biol. 2023; 6(1):1248.

PMID: 38071238 PMC: 10710489. DOI: 10.1038/s42003-023-05645-w.

Pattern Recognition Receptor Signaling and Cytokine Networks in Microbial Defenses and Regulation of Intestinal Barriers: Implications for Inflammatory Bowel Disease.

Abraham C, Abreu M, Turner J Gastroenterology. 2022; 162(6):1602-1616.e6.

PMID: 35149024 PMC: 9112237. DOI: 10.1053/j.gastro.2021.12.288.

Intralesional and peripheral plasma of oral lichenoid reactions exhibit different cytokine profiles: A preliminary study.

Sun K, Deng Y, Chen J, DU G, Song C, Chen J J Dent Sci. 2022; 17(1):256-263.

PMID: 35028046 PMC: 8739244. DOI: 10.1016/j.jds.2021.03.012.

References

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

Chen M, Yang Z, Wu R, Nadler J . Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology. 2002; 143(6):2341-8. DOI: 10.1210/endo.143.6.8841. View

Burmester G, Kremer J, Van den Bosch F, Kivitz A, Bessette L, Li Y . Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10139):2503-2512. DOI: 10.1016/S0140-6736(18)31115-2. View

Coon M, Diegel M, Leshinsky N, Klaus S . Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol. 1999; 163(12):6567-74. View

Liu L, Okada S, Kong X, Kreins A, Cypowyj S, Abhyankar A . Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011; 208(8):1635-48. PMC: 3149226. DOI: 10.1084/jem.20110958. View

Hedl M, Yan J, Abraham C . IRF5 and IRF5 Disease-Risk Variants Increase Glycolysis and Human M1 Macrophage Polarization by Regulating Proximal Signaling and Akt2 Activation. Cell Rep. 2016; 16(9):2442-55. PMC: 5165654. DOI: 10.1016/j.celrep.2016.07.060. View

Takeda K, Clausen B, Kaisho T, Tsujimura T, Terada N, Forster I . Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999; 10(1):39-49. DOI: 10.1016/s1074-7613(00)80005-9. View

Sandborn W, Feagan B, Loftus Jr E, Peyrin-Biroulet L, Van Assche G, DHaens G . Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020; 158(8):2123-2138.e8. DOI: 10.1053/j.gastro.2020.01.047. View

Pattison M, MacKenzie K, Arthur J . Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol. 2012; 189(6):2784-92. PMC: 3443740. DOI: 10.4049/jimmunol.1200310. View

10.

OShea J, Schwartz D, Villarino A, Gadina M, McInnes I, Laurence A . The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66:311-28. PMC: 5634336. DOI: 10.1146/annurev-med-051113-024537. View

11.

Yang Z, Chen M, Fialkow L, Ellett J, Wu R, Nadler J . Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci. 2003; 1005:409-11. DOI: 10.1196/annals.1288.069. View

12.

Abraham C, Medzhitov R . Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology. 2011; 140(6):1729-37. PMC: 4007055. DOI: 10.1053/j.gastro.2011.02.012. View

13.

Seok J, Warren H, Cuenca A, Mindrinos M, Baker H, Xu W . Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013; 110(9):3507-12. PMC: 3587220. DOI: 10.1073/pnas.1222878110. View

14.

Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A . Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut. 2002; 51(3):379-85. PMC: 1773344. DOI: 10.1136/gut.51.3.379. View

15.

Lahiri A, Abraham C . Activation of pattern recognition receptors up-regulates metallothioneins, thereby increasing intracellular accumulation of zinc, autophagy, and bacterial clearance by macrophages. Gastroenterology. 2014; 147(4):835-46. PMC: 4170054. DOI: 10.1053/j.gastro.2014.06.024. View

16.

Foster S, Hargreaves D, Medzhitov R . Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007; 447(7147):972-8. DOI: 10.1038/nature05836. View

17.

Frank D, Mahajan S, Ritz J . Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999; 5(4):444-7. DOI: 10.1038/7445. View

18.

Hedl M, Sun R, Huang C, Abraham C . STAT3 and STAT5 Signaling Thresholds Determine Distinct Regulation for Innate Receptor-Induced Inflammatory Cytokines, and / Disease Variants Modulate These Outcomes. J Immunol. 2019; 203(12):3325-3338. PMC: 7261200. DOI: 10.4049/jimmunol.1900031. View

19.

Hedl M, Lahiri A, Ning K, Cho J, Abraham C . Pattern recognition receptor signaling in human dendritic cells is enhanced by ICOS ligand and modulated by the Crohn's disease ICOSLG risk allele. Immunity. 2014; 40(5):734-46. PMC: 4157904. DOI: 10.1016/j.immuni.2014.04.011. View

20.

Genovese M, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y . Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018; 391(10139):2513-2524. DOI: 10.1016/S0140-6736(18)31116-4. View